Tyck till om SwePub Sök
här!
Sökning: onr:"swepub:oai:DiVA.org:oru-110735" >
Improved clinical o...
Improved clinical outcomes in patients treated with Natalizumab for at least 11 years - Real-world data from a Swedish national post-marketing surveillance study (IMSE 1)
-
- Forsberg, Linda (författare)
- Karolinska Institutet, Department of Neuroscience, Solna, Sweden
-
- Larsson, Veronica (författare)
- Karolinska Institutet, Department of Neuroscience, Solna, Sweden
-
- Hillert, Jan (författare)
- Karolinska Institutet, Department of Neuroscience, Solna, Sweden
-
visa fler...
-
- Nilsson, Petra (författare)
- Lund University, Department of Neurology, Lund, Sweden
-
- Dahle, Charlotte (författare)
- Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden
-
- Svenningsson, Anders (författare)
- Danderyd Hospital, Department of Clinical Science, Stockholm, Sweden
-
- Lycke, Jan (författare)
- University of Gothenburg, Department of Clinical Neuroscience, Gothenburg, Sweden
-
- Landtblom, Anne-Marie (författare)
- Uppsala University, Department of Neuroscience, Uppsala, Sweden
-
- Burman, Joachim (författare)
- Uppsala University, Department of Medical Science, Uppsala, Sweden
-
- Martin, Claes (författare)
- Danderyd Hospital, Department of Clinical Science, Stockholm, Sweden
-
- Sundström, Peter (författare)
- Umeå University, Department of Science, Umeå, Sweden
-
- Gunnarsson, Martin, 1973- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology
-
- Piehl, Fredrik (författare)
- Karolinska Institutet, Department of Neuroscience, Solna, Sweden
-
- Olsson, Tomas (författare)
- Karolinska Institutet, Department of Neuroscience, Solna, Sweden
-
visa färre...
-
(creator_code:org_t)
- Sage Publications, 2023
- 2023
- Engelska.
-
Ingår i: Multiple Sclerosis Journal. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 29:Suppl. 3, s. 965-966
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- Introduction: Natalizumab (NTZ) is a highly effective disease modulatory treatment for relapsing multiple sclerosis (RMS). Post-marketing surveillance is important to evaluate the long-term safety and effectiveness in a real-world setting. To this end the “Immunomodulation and Multiple Sclerosis Epidemiology Study” (IMSE 1) was initiated upon launch of NTZ in Sweden (Aug 2006).Objectives/Aims: To follow-up the long-term effectiveness and safety of NTZ in a real-world setting.Methods: Adverse events (AEs), Serious AEs (SAEs), John Cunningham virus status (JCV) and clinical effectiveness measures; Extended Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), Symbol Digit Modalities Test (SDMT) and Multiple Sclerosis Impact Scale (MSIS-29) data were collected from the nationwide Swedish Neuro Registry (NeuroReg). Effectiveness measures were assessed using the Wilcoxon Signed Rank Test.Results: A total of 4011 NTZ patients were included in the IMSE 1 study from August 2006 until March 2023 (72% female; mean age 36 years; 80% RRMS; mean treatment duration 52 months) and 249 had been treated for at least 132 months. Of the 132-month cohort, 75% were female, the mean age was 36 years, 88% had RRMS, and the mean treatment duration was 160 months. The majority were treated with interferons and glatiramer acetate prior to NTZ (68%), where 30% (74/249) discontinued NTZ treatment; 43% (32/74) due to being JCV positive (JCV+), with a mean JCV index of 1.1±0.9 (n=66). Annualized relapse rates dropped from 0.40 in the year before treatment start to 0.04 during treatment, where 68% were entirely free of relapses and 21% had only 1 relapse during the entire treatment period (17% missing data). All clinical effectiveness measures, except EDSS showed statistically significant improvement between baseline and 132 months (p<0.05).From the entire IMSE1 cohort (N=4011), 132 SAEs have been reported to the Swedish MPA, including 9 cases (2 fatal) of progressive multifocal leukoencephalopathy (PML) of which 8 occurred between 2008 and 2012, and one in 2018.Conclusion: NTZ is generally well tolerated and displays sustained effectiveness regarding cognitive, physical and psychological measures, as well as relapse-control. Introduction of JCV testing has led to fewer treated JCV+ patients, likely explaining a drastically reduced incidence of PML.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Forsberg, Linda
-
Larsson, Veronic ...
-
Hillert, Jan
-
Nilsson, Petra
-
Dahle, Charlotte
-
Svenningsson, An ...
-
visa fler...
-
Lycke, Jan
-
Landtblom, Anne- ...
-
Burman, Joachim
-
Martin, Claes
-
Sundström, Peter
-
Gunnarsson, Mart ...
-
Piehl, Fredrik
-
Olsson, Tomas
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Multiple Scleros ...
- Av lärosätet
-
Örebro universitet